Clinical trial / 2006
Oral soluble beta-1,3-D-glucan was safe, well tolerated, and increased salivary IgA at 400 mg/day in healthy volunteers
An open phase I dose-escalation study evaluated oral soluble branched yeast beta-1,3-D-glucan (SBG) given once daily for 4 consecutive days at 100 mg/day, 200 mg/day, or 400 mg/day in groups of 6 healthy non-smoking volunteers. No drug-related adverse events were observed, and repeated serum measurements revealed no systemic absorption. Saliva immunoglobulin A concentrations increased significantly at the highest dose of 400 mg/day.
- Study type
- Open 1:1:1 dose-escalation phase I trial
- Who was studied
- 18 healthy non-smoking volunteers
- What was measured
- Safety, tolerability, systemic absorption, and salivary immunoglobulin A concentration
THE PAPER
Oral administration of a new soluble branched beta-1,3-D-glucan is well tolerated and can lead to increased salivary concentrations of immunoglobulin A in healthy volunteers.
Lehne G, Haneberg B, Gaustad P, Johansen PW, Preus H, Abrahamsen TG. Clin Exp Immunol, 2006.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.